Cascone Roberto, Carlucci Annalisa, Pierdiluca Matteo, Santini Mario, Fiorelli Alfonso
Thoracic Surgery Unit, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
Lung Cancer (Auckl). 2017 Oct 10;8:161-167. doi: 10.2147/LCTT.S105623. eCollection 2017.
Soluble major histocompatibility complex class I polypeptide-related sequence A (sMICA) is a useful marker in surveillance of lung cancer. High serum sMICA level in patients with non-small-cell lung cancer (NSCLC) seems to be a poor prognostic factor being correlated with poor differentiation and advanced stage. However, the low specificity limits its role as a single prognostic marker of NSCLC, but its evaluation, in addition to standard serum markers, could improve the staging of NSCLC. Despite promising, all current studies are insufficient to assess the real efficiency of sMICA as a prognostic marker of NSCLC, and hence, future studies are required to validate it.
可溶性主要组织相容性复合体I类多肽相关序列A（sMICA）是肺癌监测中的一个有用标志物。非小细胞肺癌（NSCLC）患者血清sMICA水平升高似乎是一个不良预后因素，与低分化和晚期相关。然而，低特异性限制了其作为NSCLC单一预后标志物的作用，但除标准血清标志物外对其进行评估可改善NSCLC的分期。尽管前景广阔，但目前所有研究都不足以评估sMICA作为NSCLC预后标志物的实际效能，因此，需要未来的研究来验证它。
